drugset / Trial / NCT01188967
Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention
Phase 2
Completed
84 enrolled
Massachusetts General Hospital
GlaxoSmithKline · collabMclean Hospital · collabNational Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this research study is to find out if an investigational drug, GSK598809 can help people who have very recently quit smoking; the investigators want to find out if continuing to take GSK598809 over six weeks can help prevent smokers from relapsing. To relapse means you "fall back" into smoking again after quitting. The investigators also want to find out if GSK598809 is safe to take without causing too many side effects.
Timeline
- Start
- 2010-08
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK598809 | Unknown | 60 mg | Oral |